Friday, November 18 2016
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Cisco (CSCO) and NextEra Energy (NEE).
Buy-rated Cisco has lost ground following the mixed quarterly report, but the stock is still up more than 10% in the year-to-date period and continues to lead the broader technology space. In the updated research report issued today, the Zacks analyst covering the stock highlights Cisco's expanding footprint in the rapidly growing security and data center market. Moreover, partnerships with the likes of Pure Storage, salesforce.com and IBM will help Cisco to gain significant traction in the data center, cloud and Internet of Things (IoT) market in the long haul. (You can read the full research report onCiscohere>> )
Amgen shares have struggled this year, but it has come back following the election as fears of restrictive pricing and regulatory strictures have eased. The analyst points to Amgen's impressive quarterly results, its portfolio of blockbuster drugs, the prospect for efficiency gains from the restructuring plan and track record of returning excess cash to shareholders through dividends and buybacks. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. (You can read the full research report onAmgenhere>> )
NextEra Energy 's shares have increased by more than 10% year-to-date but have struggled over the last quarter. NextEra Energy's reported mixed third-quarter earnings. However, the analyst likes NextEra Energy's investment in renewable generation which should boost its performance over the long haul. Favorable economic conditions in its service territories will drive demand for utility services. Strategic acquisition and asset divestment bode well for NextEra Energy. On the flip side, NextEra Energy's nature of business is subject to complex and comprehensive federal, state and other regulations. Also, concerns related to commodity price fluctuations might deter its growth to some extent. (You can read the full research report onNextEra Energyhere>> )
Other noteworthy reports we are featuring today include MasterCard (MA), AbbVie (ABBV) and eBay (EBAY).
Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
Director of Research
Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here >>>
Today's Must Read
While additional indications and expansion into new markets can drive Humira sales, the Zacks analyst emphasizes that many companies are working on bringing Humira biosimilars to the market.
The covering analyst believes that the recently announced Western Refining acquisition will transform Tesoro into a downstream powerhouse with exposure to the prolific Permian Basin.
The Zacks analyst thinks Best Buy posted sturdy third-quarter results. It is making extensive investments to upgrade its operations with special focus on developing omni-channel capacities.
The Q3 earnings beat apart, the Zacks analyst is positive on eBay's pace of building a solid foundation of structured data and artificial intelligence.
Alliance Data's third-quarter 2016 earnings beat resulted from solid segmental growth. Riding on its operational strength, the company raised its 2016 core EPS guidance.
The covering analyst thinks better-than-expected Q3 result and solid property base are encouraging. However, aggressive rental concession amid rising supply is likely to limit rent growth.
The Zacks analyst believes that strong performance of recently launched products should be able to offset the impact of the challenging market environment.
The Zacks analyst believes that Chubb's inorganic growth story will continue to impress, while the robust capital position will help the company to engage in shareholder friendly moves.
The covering analyst is bullish on Stryker owing to the growth potential of its Mako total knee system alongside strong presence in the Orthopedic, Medsurg and Neurotechnology platforms.
The Zacks analyst thinks MasterCard remains well positioned for growth given its expansion & digital initiatives. Gradual shift to electronic payments from paper-based forms should drive revenues.
J.M. Smucker beats second-quarter fiscal 2017 earnings, but sales missed the consensus. Though innovation and acquisitions will drive earnings, declining sales will remain a concern, per the Zacks analyst
The covering analyst thinks Chemed's sluggish third quarter show was primarily due to declining admission units and sluggish VITAS business. Yet, raised outlook for Roto-Rooter inspires.
H&R Block is exposed to employment related lawsuits and compliance fee litigation, which weigh on investor sentiment and hamper goodwill. Adverse foreign currency translation remains another headwind.